Prognostic characteristics of surgical stage I endometrial adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 35, Issue 5, 1996, Pages 935-940

  Konski, Andre ^a   Domenico, Don ^a   Tyrkus, Michael ^a   Irving, Douglas ^a   Neisler, James ^a   Phibbs, Garth ^a   Zeidner, Steven ^a   Eggleston, William ^a  

^a TOLEDO HOSPITAL   (United States)

Author keywords

Endometrial carcinoma; Estrogen and progesterone receptor analysis; Flow cytometric DNA content analysis; Surgical staging

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA DETERMINATION; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER;

EID: 0030586080     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(96)00189-7     Document Type: Article

References (31)

1. 1. Aalders, J.; Abeler, V.; Kolstad, P.; Onsrud, M. Postoperative external irradiation and prognostic parameters in Stage I endometrial carcinoma. Obstet. Gynecol. 56:419-426; 1980.
2. 2. Ambros, R. A.; Kurman, R. J. Identification of patients with stage I uterine endometroid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol. Oncol. 45:235-239; 1992.
3. 3. Aziz, H.; Rotman, M.; Hussain, F.; Smith, G.; Chan, E.; Choi, K.; Sohn, C.; Halpern, J.; Schwartz, D.; Aral, I.; Fruchter, R.; Serur, E. Poor survival of black patients in carcinoma of the endometrium. Int. J. Radiat. Oncol. Biol. Phys. 27:293-301; 1993.
4. 4. Britton, L. C.; Wilson, T. O.; Gaffey, T. A.; Lieber, M.; Wieand, H. S.; Podratz, K. C. Flow cytometric DNA analysis of Stage I endometrial carcinoma. Gynecol. Oncol. 34:317-322; 1989.
5. 5. Calcitchi, E.; Lobo, P. A.; Martin, M.; Mazeron, J. J.; Le Bourgeois, J. P.; Pierquin, B. The role of radiation therapy in the treatment of adenocarcinoma of the corpus uteri stage I. Acta. Radiol. Oncol. 23:461-464; 1984.
6. 6. Creasman, W. T. Announcement, FIGO stages: 1988 Revision. Gynecol. Oncol. 35:125-127; 1988.
7. 7. Dyas, C. H.; Simmons, T. K.; Ellis, N.; Austin, J. M.; Partridge, E. E.; Kilgore, L. C.; Reading, C.; Nelson, K.; Blakemore, W. S. Effect of Deoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium. Surg. Gynecol. Obstet. 174:133-136; 1992.
8. 8. Enomoto, T.; Fujita, M.; Inoue, M.; Rice, J. M.; Nakajima, R.; Tanizawa, O.; Nomura, T. Alterations of the p53 tumor suppresor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res. 53:1883-1888; 1993.
9. 9. Gal, D.; Recio, F. O.; Zamurovic, D. The new international federation of gynecologic and obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer 69:200-202; 1992.
10. 10. Hendrickson, M.; Martinez, A.; Ross, J.; Kempson, R.; Eifel, P. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6:93-108; 1982.
11. 11. Hendrickson, M.; Ross, J.; Eifel, P.; Cox, R.; Martinez, A.; Kempson, R. Adenocarcinoma of the endometrium: Analysis of 256 cases with carcinoma limited to the uterine corpus. Gynecol. Oncol. 13:373-392; 1982.
12. 12. Hetzel, D. J.; Wilson, T. O.; Keeney, G. L.; Roche, P. C.; Cha, S. S.; Podartz, K. C. HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol. Oncol. 47:179-185; 1992.
13. 13. Ignar-Trowbridge, D.; Risinger, J. I.; Dent, G. A.; Kohler, A.; Berchuck, A.; McLachlan, J. A.; Boyd, J. Mutations of the Ki-ras oncogene in endometrial carcinoma. Am. J. Obstet. Gynecol. 167:227-232; 1992.
14. 14. Ikeda, M.; Watanabe, Y.; Nanjoh, T.; Noda, K. Evaluation of DNA ploidy in endometrial cancer. Gynecol. Oncol. 50:25-29; 1993.
15. 15. Ingram, S. S.; Rosenman, J.; Heath, R.; Morgan, T. M.; Moore, D.; Varia, M. The predictive value of progesterone receptor levels in endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 17:21-27; 1989.
16. 16. Kacinski, B. M.; Carter, D.; Mittal, K.; Kahorn, E. I.; Bloodgood, R. S.; Donahue, J.; Donofrio, L.; Edwards, R.; Schwartz, P. E.; Chambers, J. T.; Chambers, S. K. High level expression of FMS proto-oncogene mRNA is observed in clinically aggresive human endometrial adenocarcinomas. Int. J. Radiat. Oncol. Biol. Phys. 15:823-829; 1988.
17. 17. Konski, A.; Domenico, D.; Irving, D.; Tyrkus, M.; Neisler, J.; Phibbs, G.; Bishop, K.; Mah, J.; Eggleston, W. Flow cytometric DNA content analysis of paraffin embedded tissue derived from cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 30:839-843; 1994.
18. 18. Konski, A. A.; Domenico, D.; Irving, D.; Tyrkus, M.; Neisler, J.; Phibbs, G.; Man, J.; Eggleston, W. Clinicopathologic correlation of DNA flow cytometric content analysis (DFCA), surgical staging, and estrogen/Progestrone receptor status in endometrial adenocarcinoma. Am. J. Clin. Oncol. 19:164-168; 1996.
19. 19. Konski, A. A.; Myles, J. L.; Sawyer, T.; Neisler, J.; Phibbs, G.; Leininger, S.; Kim, K.; Dobelbower, R. R. Flow cytometric DNA content analysis of paraffin block embedded endometrial carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 21:1033-1039; 1991.
20. 20. Kuipers, T. J. The role of radiation therapy in conjunction with surgery in the treatment of endometrial carcinoma. In: Heintz, ed. Surgery in gynecologic oncology. Amsterdam: Martinus Nijhoff; 1984:236-247.
21. 21. Liao, B. S.; Twiggs, L. B.; Leung, B. S.; Yu, W. C. Y.; Polish, R. A.; Prem, K. A. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet. Gynecol. 67:463-467; 1986.
22. 22. Marchetti, D. L.; Piver, M. S.; Tsukada, Y.; Reese, P. Prevention of vaginal recurrence of stage I endometrial adenocarcinoma with postoperative vaginal radiation. Obstet. Gynecol. 67:399-402; 1986.
23. 23. Meerwaldt, J. H.; Hoekstra, J. M.; Van Putten, W. L. J.; Subandono Tjokrowardojo, A. J.; Koper, P. C. M. Endometrial adenocarcinoma, adjuvant radiotherapy tailored to prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 18:299-304; 1990.
24. 24. Melchiorri, C.; Chieco, P.; Lisignoli, G.; Marabini, A.; Orlandi, C. Ploidy disturbances as an early indicator of intrinsic malignancy in endometrial carcinoma. Cancer 72:165-172; 1993.
25. 25. Mizuuchi, H.; Nasim, S.; Kudo, R.; Silberberg, S. G.; Greenhouse, S.; Garrett, C. T. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res. 52:2777-2781; 1992.
26. 26. Moberger, B.; Auer, G.; Forsslund, G.; Moberger, G. The prognostic significance of DNA measurements in endometrial carcinoma. Cytometry 5:430-436; 1984.
27. 27. Morrow, C. P.; Bundy, B. N.; Kurman, R. J.; Creasman, W. T.; Heller, P.; Homesly, H. D.; Graham, J. E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group Study. Gynecol. Oncol. 40:55-65; 1991.
28. 28. Orr, J. W.; Holloway, R. W.; Orr, P. F.; Holimon, J. L. Surgical staging of uterine cancer: An analysis of perioperative morbidity. Gynecol. Oncol. 42:209-216; 1991.
29. 29. Rosenberg, P.; Boeryd, B.; Simonsen, E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol. Oncol. 48:32-37; 1993.
30. 30. Rosenberg, P.; Wingren, S.; Simonsen, E.; Stal, O.; Risberg, B.; Nordenskjold, B. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: An important prognostic indicator. Gynecol. Oncol. 35:50-54; 1989.
31. 31. Toonkel, L. M.; Fix, I.; Jacobson, L. H. Myometrial penetration of endometrial carcinoma as a prognostic factor for patients receiving pre- or postoperative radiation therapy. Am. J. Clin. Oncol. 7:669-673; 1984.